Highlights
- Peri-operative myocardial infarction/injury (PMI) is a frequent and often clinically silent complication of non-cardiac surgery associated with poor long-term prognosis.
- Prospective multicentre data indicates that specialist cardiologist evaluation of patients with PMI is independently associated with a 46% reduction in major adverse cardiac events (MACE) at one year.
- The survival benefit (35% reduction in all-cause mortality) is largely driven by increased utilization of non-invasive cardiac imaging and evidence-based secondary prevention (DAPT and statins).
- Interdisciplinary ‘Heart Team’ models are essential for translating biomarker-detected myocardial injury into actionable, life-saving clinical management.
Background
Peri-operative myocardial infarction/injury (PMI), which encompasses both myocardial infarction and myocardial injury after non-cardiac surgery (MINS), represents one of the most significant predictors of post-operative morbidity and mortality. With the aging population and the increasing complexity of surgical procedures, the incidence of PMI remains high, occurring in approximately 10–15% of high-risk patients. Unlike spontaneous myocardial infarction, the vast majority of PMI cases (over 80%) occur without typical ischemic symptoms such as chest pain, primarily due to the residual effects of anesthesia, analgesia, and the confounding nature of surgical site pain.
Because most PMI cases are detected solely through routine troponin surveillance rather than clinical symptoms, a management gap has emerged. While surgical teams are proficient in managing technical and post-operative surgical complications, the nuances of cardiovascular risk stratification and the management of myocardial injury often fall outside their primary expertise. Historically, it has been unclear whether a formal cardiologist consultation—beyond standard surgical care—modulates the long-term clinical trajectory of these patients. This article synthesizes the latest evidence regarding the impact of cardiology involvement on post-operative outcomes, focusing on the milestone Glarner et al. (2026) study.
Key Content
The Epidemiology and Prognosis of PMI
The transition from diagnosing only symptomatic myocardial infarction to identifying troponin-defined myocardial injury (MINS) has revealed a massive “silent” epidemic. Large-scale observational studies, such as the VISION study, have consistently demonstrated that even isolated troponin elevations in the peri-operative period are independently associated with a significantly higher risk of 30-day and 1-year mortality. Despite this prognostic clarity, the therapeutic pathway for an asymptomatic troponin elevation remains a subject of debate in clinical guidelines.
Cardiologist Evaluation: A Natural Experiment
The study by Glarner et al., published in the European Heart Journal, provides the most robust evidence to date on the efficacy of specialist intervention. Utilizing a unique prospective cohort of 14,294 high-risk patients, the researchers leveraged a “natural experiment” created by staffing constraints. Cardiologist evaluation was available for patients developing PMI on weekdays but was inconsistently available on weekends and public holidays. This allowed for a comparison between patients who received a specialist consult and those who did not, minimizing the selection bias often found in physician-referred cohorts.
Of the 1,048 patients who developed PMI, 58.6% received a cardiology evaluation. Despite having similar baseline characteristics, the two groups diverged significantly in their one-year outcomes. The primary endpoint—a composite of cardiovascular death, MI, heart failure, and life-threatening arrhythmia—was significantly lower in the cardiology-evaluated group (Adjusted Hazard Ratio [aHR] 0.54, 95% CI 0.37–0.78; P = 0.001).
Mechanisms of Therapeutic Benefit
The disparity in outcomes can be traced to the specific diagnostic and therapeutic actions initiated by the cardiology specialists. Synthesis of the study data reveals several key intervention domains:
- Enhanced Diagnostic Precision: Patients seen by a cardiologist were significantly more likely to undergo non-invasive cardiac imaging, primarily echocardiography. This allowed for the identification of previously unrecognized structural heart disease, valvular issues, or regional wall motion abnormalities that informed subsequent management.
- Pharmacological Optimization: The cardiology-evaluated group showed a higher rate of initiation of Dual Antiplatelet Therapy (DAPT) and high-intensity statins. These medications address the underlying pathophysiology of both Type 1 MI (plaque rupture) and the heightened inflammatory state of the peri-operative period.
- Secondary Prevention and Follow-up: Cardiologists were more likely to establish a long-term cardiovascular care plan, ensuring that the acute peri-operative event was treated as a signal of high chronic risk requiring outpatient management.
Evidence by Disease Subtype: Type 1 vs. Type 2 Injury
PMI is heterogeneous. Type 1 MI involves plaque rupture, whereas Type 2 is driven by supply-demand mismatch (tachycardia, anemia, hypotension). Evidence suggests that cardiologist evaluation is particularly effective because specialists are trained to differentiate these phenotypes using subtle ECG changes and clinical context, tailoring interventions like coronary angiography to those most likely to benefit while avoiding unnecessary risks in patients with supply-demand mismatch.
Expert Commentary
The findings by Glarner and colleagues highlight a critical “human factor” in modern healthcare: the value of specialized clinical judgment in the face of complex biomarker data. In the era of high-sensitivity troponin assays, there is a risk of “troponin fatigue,” where surgical teams may become desensitized to small elevations. The 46% reduction in MACE associated with cardiology consultation is a staggering effect size, comparable to or exceeding many well-established pharmacological interventions in cardiovascular medicine.
However, several controversies remain. First, the “weekend effect” suggests that health systems must address staffing disparities to ensure equitable care. Second, the cost-effectiveness of mandatory cardiology consults for all troponin elevations needs further study, as this would place a significant burden on cardiology departments. The focus should likely be on high-risk patients identified through rigorous surveillance programs, such as the BASEL-PMI model.
Mechanistically, the benefit likely stems from the aggressive management of Type 1 MI that would otherwise go untreated. By identifying patients who require coronary intervention or robust antiplatelet therapy, cardiologists prevent the subsequent MI or cardiovascular death that typically occurs within the first 6–12 months post-surgery.
Conclusion
The involvement of cardiologists in the management of patients with peri-operative myocardial infarction or injury is not merely a diagnostic luxury but a prognostic necessity. Evidence confirms that cardiologist evaluation is independently associated with a marked reduction in long-term mortality and major adverse cardiac events. This benefit is mediated through superior diagnostic workup and the timely initiation of secondary preventive therapies.
Moving forward, hospitals should prioritize the development of integrated peri-operative care pathways that mandate cardiologist involvement when myocardial injury is detected. Future research should focus on refining the risk-stratification tools that trigger these consultations to optimize resource allocation without compromising the significant survival benefits observed in recent clinical evidence.
References
- Glarner N, et al. Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes. European Heart Journal. 2026;47(12):1470-1483. PMID: 41610880.
- Devereaux PJ, et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012;307(21):2295-2304. PMID: 22706835.
- Devereaux PJ, et al. Dabigatran in patients with myocardial injury after noncardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018;391(10137):2325-2334. PMID: 29891405.
- Writing Committee for the VISION Study Investigators. Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality in Noncardiac Surgery. JAMA. 2017;317(16):1642-1651. PMID: 28444045.
